Biotech Business - February 1, 2022
BioInvent granted Orphan Drug Designation by the FDA
BioInvent International has announces that its anti-FcyRllB antibody BI-1206 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of follicular lymphoma, the most common form of slow-growing Non-Hodgkin lymphoma. BI-1206 previously received ODD from the FDA for the treatment of mantle cell lymphoma (MCL) in January 2019. BI-1206 […]
Biotech Business - January 24, 2022
Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US
The company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto (INN melphalan flufenamide, also called melflufen) in the US. Further review and analyses of the heterogenous Overall Survival data from the phase 3 OCEAN study and other relevant trials have […]
Biotech Business - January 19, 2022
Elicera Therapeutics secures 5 million SEK
Elicera Therapeutics has announced that Vinnova has granted the company and its project partners 5 million SEK in grants to develop an automated process for CAR T-cell manufacturing. Elicera Therapeutics and its collaborators at Karolinska Institute and their production unit, Vecura at Karolinska Sjukhuset, Uppsala University and Akademiska Sjukhuset in Uppsala are preparing for a […]
Biotech Business - January 19, 2022
Oasmia changes name and resolves a new issue of shares
The Board of Directors of Oasmia has resolved on a new issue of shares with preferential rights for existing shareholders of approximately SEK 151 million. The purpose of the Rights Issue is to finance the continued development of the company and its projects in accordance with its business plan and strategy, it states. Shareholders in […]
Biotech Business - January 12, 2022
Affibody and Lokon Pharma initiate collaboration
Lokon Pharma has announced a collaboration with Affibody to combine oncolytic viruses with Affibody molecules. “Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already have one virus in clinical development, LOAd703, and we are expanding our pipeline to meet the demand of different types of malignancies” says […]
Biotech Business - January 10, 2022
Valo Therapeutics acquires IP rights from the University of Helsinki
Valo Therapeutics has announced the acquisition of intellectual property rights from the University of Helsinki for the technology which utilizes pre-existing immunity (PEI) against pathogens to enhance the therapeutic efficacy of ValoTx’s lead platform, PeptiCRAd. This approach takes advantage of existing acquired immunity (generated, for example, through vaccination against pathogens) by including pathogen specific peptides […]
